Monthly Archives: March 2011

Value-Based Pricing Could Counter Innovation, Says UK Think Tank

By Julian Upton | Published: March 25, 2011
The UK government’s proposals to introduce value-based pricing (VBP) — which aims to create a stronger link between the price the National Health Service pays for a medicine and the value it delivers (and in the process, ostensibly, further incentivize therapeutic innovation) — could actually serve to ‘hinder’ innovation, according to a UK think tank.
Posted in Europe, Global, R&D, pricing | Tagged , , , , , , | Leave a comment

First Chinese Product Development Partnership Targets Tuberculosis, Malaria, AIDS

By Ben Comer | Published: March 24, 2011
A Chinese scientific foundation and a not-for-profit tuberculosis organization announced a partnership aimed at developing new medicines for underserved public health diseases. Billed as the first Chinese product development partnership (PDP), the Global Health R&D Center of China (GHRC) hopes to discover and develop new treatments for tuberculosis (TB) and other diseases by collaborating with pharmaceutical [...]
Posted in Biotech, Corporate Responsibility, Deals, Emerging Markets, Global, IP, Market Access, R&D, Technology, patient compliance | Tagged , | Leave a comment

Two 'Most Promising' New Drugs Face Setbacks in US

By Ben Comer | Published: March 22, 2011
Two of the drugs named “most promising” in Thomson Reuters’ recent quarterly report hit snags in the US, despite European approval. Those two products – AstraZeneca’s Brilique (Brilinta in the US), a blood thinner, and Pharming’s Ruconest (Rhucin in the US) – were held up during FDA’s review process. Brilique (ticagrelor), AstraZeneca’s leading pipeline drug, was [...]
Posted in FDA, Global, R&D, Regulatory, Sales | Tagged , , , , , | Leave a comment

Assessing the Future State of Industry R&D: Panic, Prosperity or Both?

By Julian Upton | Published: March 16, 2011
Home to a large segment of the global biopharma industry, the state of New Jersey has a significant stake in the future of medicines innovation.  An annual symposium convened by the Rutgers University School of Business attempts to monitor the pulse of industry progress through an increasingly daunting thicket of commercial and policy challenges. This year’s [...]
Posted in Events, Global | Leave a comment

Industry Reactions to Japan Earthquake Crisis

By Julian Upton | Published: March 16, 2011
As a dazed Japan copes with the aftermath of the Tohoku earthquake, Japanese pharma companies have been quick to offer donations of both money and medical supplies and help with aid efforts. Takeda has pledged 300m Japanese Yen ($3.6m) to the Japanese Red Cross Society to help the emergency relief fund, as well as offering [...]
Posted in Global | Tagged , , , , , , | Leave a comment